Bellando-Randone Silvia, Matucci-Cerinic Marco
Department of Experimental and Clinical Medicine, University of Florence, V. Pieraccini 18, 50139, Florence, Italy.
Department of Geriatric Medicine, Division of Rheumatology, AOUC, Florence, Italy.
Curr Rheumatol Rep. 2017 Sep 18;19(10):65. doi: 10.1007/s11926-017-0684-2.
The approach to systemic sclerosis (SSc) has changed over the years with an increasing focus on the very early diagnosis of the disease. The terminology identifying patients in the early phase of SSc has been significantly confusing in the last three decades. The purpose of this article is to analyze how the concept of "very early SSc" has evolved over the years, which is the role of an early diagnosis and how early treat patients.
Several attempts have been made over time, to create more sensitive and specific classification criteria to include the largest number of SSc patients, also in the earliest phase. An algorythm for the very early diagnosis of SSc was identified, diagnostic preliminary criteria proposed, and new 2013 ACR/EULAR SSc classification criteria published, including new items and adding emphasis to the vasculopathic manifestations. True biomarkers that could predict the disease evolution are still missing. Treat or not to treat patients in the earliest phases still remain a dilemma. For the moment, the only feasible clinical strategy in very early SSc remains a tight follow up program to detect in "real time" the early internal organ involvement which may allow an aggressive therapeutic agenda.
多年来,系统性硬化症(SSc)的治疗方法不断变化,对疾病的极早期诊断愈发重视。在过去三十年里,用于识别SSc早期患者的术语一直非常混乱。本文旨在分析“极早期SSc”的概念多年来是如何演变的,早期诊断的作用以及如何尽早治疗患者。
长期以来,人们多次尝试制定更敏感、更具特异性的分类标准,以纳入最多数量的SSc患者,包括最早期的患者。确定了一种用于SSc极早期诊断的算法,提出了诊断初步标准,并发布了2013年美国风湿病学会/欧洲抗风湿病联盟(ACR/EULAR)SSc新分类标准,其中包括新条目并更加强调血管病变表现。目前仍缺乏能够预测疾病进展的真正生物标志物。是否在最早期治疗患者仍然是一个难题。目前,极早期SSc唯一可行的临床策略仍是严密的随访计划,以便“实时”检测早期内脏器官受累情况,从而制定积极的治疗方案。